Category: Other

In:  Other  

How to turn an idea into reality? An interview with Dr. Raphael Hofstein, President and CEO of MaRS Innovation

Raphael crop 6073

Across the street from the venerable University of Toronto, at the intersection of College Street and Elizabeth Street in downtown Toronto, you will find the heart of Toronto’s commercialization activity across the sciences: MaRS Innovation.

If you share the values of Marc Andreessen, the American entrepreneur, investor and software developer who revolutionized a very small part of San Francisco to become the world famous Silicon Valley, you will appreciate learning about the contemporary Canadian version of biomedical Silicon Valley. MaRS Innovation was founded in 2008 and began operations in 2009 to turn Toronto’s leading research and sciences into successful start-up companies and license deals.

I really love this part of Toronto. I used to tackle my research on zebrafish heart development on the 11th floor of the MaRS building’s East Tower (MaRS Innovation’s offices occupy part of the 4th floor on the West Tower). So, I am no stranger to Toronto’s life sciences scene. But the story of how MaRS Innovation landed in Toronto and found its home is worth sharing.

Prior to the 8th Charité Entrepreneurship summit in Berlin, Germany, I spoke to Dr. Raphael Hofstein, president and CEO of MaRS Innovation about his vision for open access and open innovation models. Here is what he had to say.

Q1: What is MaRS Innovation: an innovation hub, a medical and health care technology accelerator/incubator or all of that together?

RH: We are the outcome of the Government of Canada’s fairly tenacious campaign to close the gap between Canada’s highly-qualified scientific research and its commercialization success. So, we really try to help start-ups bridge the “valley of death” and we do that in a very distinct way. Particularly, every new exciting research idea coming out of the 15 institutions in and around the Toronto area is disclosed to MaRS Innovation. As the agency of these 15 member institutions, we have to select the ideas with the best chances of successful commercialization in the shortest possible time. That is essentially what MaRS Innovation is: a research and innovation pipeline.

Every year, scientific organizations disclose between two and 15 intended projects; we select approximately 15 per cent of what we see. Since 2009, we have seen about 1500 ideas, which we successfully converted under our management into over 100 technologies. Some of them turned into start-up companies, or options/licenses to a third-party or private sector entity. Other inventions are blended or packaged together and to be more appealing to the market.


Source: MaRS Innovation One Pager May 2015

Q2: How do you see a role of open access and open innovation processes in life sciences?

RH: To highlight open innovation models in life sciences, I would like to emphasize that there are different understandings of this process. So, I need to specify an invisible margin where life sciences research should be open, and where interaction with business should not be transparent. Personally, I am for open access and open data sharing, which should benefit scientists, medical doctors, and entrepreneurs, especially at the initial stage of discovery. Later on, the research becomes industry-driven and requires a proper investment from the private sector, including big pharma and life sciences industry. Let me give you one most recent example.

Due to a successful partnership with Quebec-based Consortium for Drug Discovery (CQDM), MaRS Innovation founded a company named Encycle Therapeutics, a University of Toronto biotechnology start-up. Interestingly, being a start-up venture, Encycle has two sub-divisions. One addresses the basic essence of all CQDM activities and represents an open innovation part; using the chemistry of peptides to develop an approach to synthesizing small, drug-like macrocycles. Encycle is creating a library of cyclic peptides, called nacellins, which are small macrocycles or cyclic peptidomimetics. This library is completely open and freely available to every pharma outlet who is interested in testing or developing orally bioavailable modulators of proteins, including small-cell permeable systems. That approach fits well positioned into a concept of open access. The other Encycle subdivision is commercially focused and working with industry partners to create proprietary technologies.

Another example is the adoption of embryonic stem cell lines for medical repair. Such cell lines should serve as a foundation for the further development of cell-based technologies and the public should have free access to it. As soon as it concerns further derivation and differentiation of stem cell lines for specific medical indications, it becomes part of proprietary ownership to the developer/investor since it requires a substantial investment into research and development. That part should be closed for public use.

As we can see, a major issue of open innovation remains on where we have to draw a borderline between the public and private use. In terms of the drug discovery process, I believe it could be at phase 1 stage of clinical development.

In Toronto, we have a very strong advocate of open access and open innovation, Dr. Aled Edwards. Aled Edwards leads the Structural Genomics Consortium (SGC), a private-public open collaborative network of researchers from the University of Toronto, the University of Oxford, UK and the State University of Campinas (Unicamp) in Brazil working together with nine global pharmaceutical companies and several research funding agencies. This is a unique, first open science international institution that offers completely free access and use of research results focused on unrestricted drug discoveries. I think it is a great example of open innovation in practice. However, in later stages, clinical development requires appropriate investments and, in reality, cannot be supported through open access. Therefore, I see managing this process as the technologies develop as quite challenging in its practical realities.

Q3: Do you think that big data, open science, and a worldwide network could in the future precisely tailor therapies to each patient’s individual requirements?

RH: I am a big proponent of big data. I think an open innovation model in big data science may play a greater role. At MaRS Innovation, we engage with IBM and several venture capital groups working on harnessing big data for medical purposes. Also, pharma companies expressed strong interest in having access to medical records which represent a high-value ‘big data treasure’ within our member institutions. However up to now, it has not been easy to fulfil our dreams of turning big data into a big practical opportunity. It is obviously a work in progress! Finally, it is my expectation that mining through big data collections of patient medical records (contingent on strict patient privacy!) will significantly accelerate the development of precision medicine (aka personal medicine). The global medical community should be prepared to address the trend.

In:  Other  

ArXiv successfully racing toward the one million mark – what happens now?

  • About 24 years after its launch the arXiv preprint server hits 1 million articles on 29 December. The site reached that terrific target after administrators returned from holidays and updated the server with manuscripts submitted after business hours on Christmas Eve, Richard van Norden said in his report in Nature. Impressively more and more papers were posted as preprints from year to year, starting from a few hundred in the early nineties, when Paul Ginsparg initiated the arXiv site, to about 10,000 per months meanwhile.

    “Kudos to Paul Ginsparg and the arXiv team for this achievement.” (Peter Suber, 2014)

    Since more than two decades particularly physicists, mathematicians, and computer scientists were used to upload their manuscripts to arXiv to share their results with peers as a preprint prior to the submission to a standard scholarly journal. When I was working as a physicists myself, I also regularly used as a resource to browse and access the most recent findings of my colleagues. And I definitely know that I had been not the only guy who started his work in the morning in this way. The advantage of the arXiv to publicly share recent results of scholarly research has been quite obvious: only a few hours or days after a competing group had finished their draft to summarize their findings, researchers were able to read them without any delay and without any restrictions for access. Possibly this has been also one aspect which contributed to that story of success which now results in one million posts on arXiv. As an another result, most publishers meanwhile accept submissions from arXiv.
    Preprint-posts on the arXiv are not peer-reviewed because managing and controlling of that filtering process had been the monopoly of scholarly journals for decades. Nevertheless one may ask if we do need something outside the ArXiv? I discussed this question in a blog almost a year ago, based on the perspective of physicists and their attitude to foster Open Access. This question, or more generally the basic idea to combine a well-established preprint server, as the ArXiv, with something to enable and moderate the scientific discourse as a substitute of the classical peer-review process was raised some years ago by Field’s medalist Timothy Gowers. In 2011 Gowers asked in one of his blog posts how we might get to a new model of (scientific) publishing, however focused, but principally not limited, to mathematics. His visionary thoughts had been motivated by an earlier post by Michael Nielsen. Gowers suggested “something like a cross between the arXiv, a social networking site, Amazon book reviews, and Mathoverflow”. In a very systematic way, he further developed his smart idea, or his gedankenexperiment as a physicist would call it, as an “ideal world” towards future scholarly communication. The proposed (non-existing) website should be an extension of the arXiv, or simply a separate website with links to articles which were hosted at arXiv.

    “If we didn’t have journals, then what might we have instead?” (Timothy Gowers, 2011)

    Here we are: The scientific community which had been used to regularly post and access recent findings on the arXiv would then be invited to comment, rate, and discuss new posts. I personally like that concept which is straightforward and based on the experiences and the behavior of researchers over two decades. Despite the fact that the latter oberservation is true mostly for researchers from physics, mathematics and computational sciences it could be adopted in principal to all disciplines of scholarly research. Amazingly, I read Timothy Gowers’s excellent blog some time after it had been published when I had already developed the concept for ScienceOpen in 2013. Nevertheless, his visionary considerations to develop a new model for scholarly publishing and the following, very intensive discussion of these ideas within the community strongly supported me to continue developing a new website which fosters not only Open Access, but also consists of a community-based concept to evaluate scientific results in an open and transparent manner. I am confident that future workflows for publishing and quality assessment in science will be based on these principles.

    Let’s see if ScienceOpen can further contribute to this vision in 2015! Have a great start into the new year!

  • In:  Other  

    ScienceOpen Interview with David Black, Secretary General, International Council for Science.

    David Black is Secretary General of the International Council for Science (ICSU) and Professor of Organic Chemistry at the University of New South Wales, Australia. An advocate of Open Access for scientific data in his role at ICSU, Professor Black is a proponent of the initiatives of ICSU and ICSU-affiliate groups, such as the Committee on Freedom and Responsibility in the Conduct of Science (CFRS), the ICSU-World Data System (ICSU-WDS), the International Council for Scientific and Technical Information (ICSTI), the ICSU’s Strategic Coordinating Committee on Information and Data (SCCID), Continue reading “ScienceOpen Interview with David Black, Secretary General, International Council for Science.”  

    In:  Other  

    Open Access in Physics: Do we need something outside the arXiv?

    Over the last few days I attended the Spring Meeting of the German Physical Society (DPG) in Berlin. Physicists are considered sometime as a very special species among scientists, and not only because the characters introduced in the “Big Bang Theory” sitcom. Physicists developed the World Wide Web in the late eighties which became the starting point for all internet activities today. In 1991 Paul Ginsparg started to post preprints of research articles in a repository at Los Alamos National Laboratory which is known as “arXiv” ( ) which now consists of more than Continue reading “Open Access in Physics: Do we need something outside the arXiv?”  

    In:  Other  

    2014 – A good year for Open Access publishing?

    2014: The year is off to a good start for the Open Access movement. In the US, Congress passed legislation to require that all research funded by public funding bodies be freely accessibly, at least in the author’s final version and with a 12 month embargo after publication. (Peter Suber has a good summary of the legislation in his blog: ) Will this continue a trend started by the National Institute of Health and its public access database PubMedCentral (PMC – ) to increasingly direct readers to the pre-typeset version of an article? Phil Davis of the Continue reading “2014 – A good year for Open Access publishing?”  

    Next page